Crossmark

Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer

Published Online: 2022-09-23

Published Print: 2022-12

Authors

Yokota, Hayato

Sato, Kazuhiro

Sakamoto, Sho

Okuda, Yuji

Fukuda, Natsuki

Asano, Mariko

Takeda, Masahide

Nakayama, Katsutoshi

Miura, Masatomo
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (22H04281, 20K07150)
License Information

Text and Data Mining valid from 2022-09-23

Version of Record valid from 2022-09-23
More Information

Article History

Received: 4 August 2022

Accepted: 12 September 2022

First Online: 23 September 2022

Declarations

:

: The study was conducted according to the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Akita University School of Medicine (approval numbers: 790 and 1140).

: Informed consent was obtained from all participants enrolled in this study.

: The authors have no relevant financial or nonfinancial interests to disclose.

Document is current